11th 3D Tissue Models Summit 2026

Regulatory and governmental momentum is forcing change, fast:

The Senate have recently cleared the FDA Modernization Act 3.0
The FDA have developed a roadmap that’s abandoning animal testing for mAbs
NIH have closed the door on animal-only grants
The UK join the plan to phase out animal testing, announced by the Science Minster Lord Vallance

Meanwhile, your pipelines are chasing novel targets that in vivo models can't predict.

The 11th 3D Tissue Models Summit is where the industry comes to solve this. As the only industry-led forum dedicated to advancing organoids, organ-on-chip, and MPS, you'll connect with scientists from AbbVie, Novartis, Vertex, and many more who are validating these models, securing regulatory buy-in, and making them work at scale. The shift is happening, so make sure your organization is ready.

URLs:
Tickets: https://go.evvnt.com/3430774-2?pid=185 
Brochure: https://go.evvnt.com/3430774-3?pid=185 

Date and Time: Tue, 28 Apr 2026 09:00 - Thu, 30 Apr 2026 16:05

Venue details: Hyatt Regency Boston, One Avenue de Lafayette, Boston, Massachusetts, 02111, United States

Category: Conferences | Science, Health & Medicine

Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 4397.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3748.00,
Drug Developer Pricing - Conference Only: USD 3099.00,
Academic Pricing - Conference + 2 Workshops: USD 3797.00,
Academic Pricing - Conference + 1 Workshop: USD 3248.00,
Academic Pricing - Conference Only: USD 2699.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 5297.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 4548.00,
Solution Provider Pricing - Conference Only: USD 3799.00

Speakers: Munzareen Khan, Senior Scientist II, AbbVie, Nida Khan, Senior Scientist, AbbVie, Sandeep Joshi, Senior Scientist, AbbVie, Malini Iyer, Associate Director, AstraZeneca, Colin Choi, Associate Scientific Director, Biogen, Christopher Hinckley, Head, Cellular Models and Molecular Biology, Biogen, Bilal Cakir, Associate Principal Scientist, Merck, Stephan Krieg, Scientist, Merck, Timothy Petrie, Principal Scientist, Novo Nordisk, Rachelle Prantil-Baun, Principal Scientist, Novo Nordisk, Bindu Sukumaran, Senior Principal Scientist, Novartis, Gizem Rizki, Senior Principal Scientist, Novartis, Regis Doyonnas, Senior Principal Scientist and Associate Fellow - Research, Pfizer, Elham Malekzadeh, Senior Scientist, Takeda, Jason Ekert, Head, Neuromuscular Focus Area and Translational Biology, UCB, Clara Morral Martinez, Research Investigator, Incyte Corporation, Hailey Cambra, Gene Editing Research Scientist, Vertex Pharmaceuticals, Graham Marsh, Scientific Director Critical, Path Institute, Megan LaFollette, Executive Director, The 3R Collaborative